Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to outsmart treatment-resistant prostate cancer

NCT ID NCT06145633

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 31 times

Summary

This study tests whether adding vorinostat (a drug that may make cancer cells more sensitive) to a standard radioactive therapy (177Lu-PSMA-617) can help men whose advanced prostate cancer has low levels of a specific marker (PSMA). About 15 men with castration-resistant prostate cancer that has spread will receive both drugs. The goal is to see if the combination can turn the cancer into a type that responds better to the radioactive treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8